Zantac

Common Uses

Zantac is primarily used to reduce the amount of acid produced in the stomach. It is frequently used for the following conditions:

• Heartburn and Acid Indigestion: Relieving and preventing heartburn caused by eating or drinking certain foods and beverages.
• Gastroesophageal Reflux Disease (GERD): Treating the symptoms of acid reflux, where stomach acid backs up into the food pipe (esophagus).
• Stomach and Intestinal Ulcers: Treating active ulcers and preventing them from returning after they have healed.
• Erosive Esophagitis: Healing and managing inflammation or damage to the lining of the esophagus caused by excess acid.

Other Conditions

In some cases, healthcare providers may prescribe this medication for rare conditions where the stomach produces too much acid, such as Zollinger-Ellison syndrome. While the original Zantac products containing ranitidine were removed from the market due to safety concerns, current versions of the brand (such as Zantac 360) use famotidine to treat these same acid-related issues.

How Zantac Works

Zantac belongs to a class of medications known as histamine-2 blockers, often called H2 blockers. These drugs work by interfering with the biological process that triggers the production of stomach acid.

The lining of the stomach contains specialized cells that release acid to help digest food. These cells have receptors on their surface called histamine-2 receptors. When a natural chemical in the body called histamine attaches to these receptors, it signals the cells to produce and release acid into the stomach.

Zantac works by binding to these H2 receptors and blocking histamine from attaching to them. By preventing this signal, the medication reduces the overall amount of acid the stomach makes. This process results in several key effects:

• A decrease in the total volume of acid secreted.
• A reduction in the concentration of acid in the stomach.
• Lower levels of acid production both during the day and at night.

By lowering the amount of acid present, the medication helps prevent irritation of the esophagus and stomach lining. This provides relief from symptoms like heartburn and acid indigestion, and it allows the body to heal damage such as ulcers or inflammation caused by excess acid.

Common Side Effects

Many individuals using this medication experience only mild symptoms. Common side effects may include:

• Headache
• Dizziness
• Constipation
• Diarrhea

Serious Side Effects

Contact a healthcare professional immediately if you experience any of the following serious symptoms:

• Mental or mood changes, such as confusion, agitation, or hallucinations
• Fast, slow, or irregular heartbeat
• Easy bruising or bleeding
• Severe stomach pain
• Yellowing of the eyes or skin (jaundice)
• Dark urine
• Seizures

Seek emergency medical attention if you notice signs of a severe allergic reaction, including a rash, swelling (especially of the face, tongue, or throat), severe dizziness, or trouble breathing.

FDA Market Action

In 2020, the FDA requested the removal of all ranitidine products (formerly sold as Zantac) from the market due to concerns regarding a contaminant called NDMA. Current products marketed under the Zantac brand name, such as Zantac 360, typically contain famotidine instead of ranitidine.

FDA Market Withdrawal

The FDA requested the immediate removal of all prescription and over-the-counter ranitidine medications from the market in April 2020. This decision followed investigations showing that a contaminant known as N-Nitrosodimethylamine (NDMA) can increase over time and when stored at higher temperatures, potentially exposing consumers to levels of this probable human carcinogen that exceed safety limits.

Contraindications and Sensitivities

Ranitidine is contraindicated in individuals with a known hypersensitivity to the drug or other H2-receptor antagonists. Allergic reactions may include skin rash, swelling, or respiratory distress.

Medical Conditions and Precautions

• Kidney Disease: Since ranitidine is primarily cleared by the kidneys, individuals with renal impairment may require dosage adjustments to prevent the drug from reaching high levels in the blood.
• Liver Disease: Caution is recommended for those with pre-existing liver conditions, as the drug is partially processed by the liver.
• Porphyria: Rare reports suggest that ranitidine may trigger attacks of acute porphyria. It is generally avoided in patients with a history of this blood disorder.

Pregnancy and Breastfeeding

Ranitidine crosses the placenta and is excreted in breast milk. It should be used during pregnancy or while nursing only if a healthcare provider determines the benefits outweigh the potential risks.

Reformulated Products

Current products sold under the Zantac brand name (such as Zantac 360) contain famotidine instead of ranitidine. The warnings and precautions for these newer products are different, and users should verify the active ingredient on the product label.

Pregnancy

The active ingredients in Zantac products are generally considered safe for use during pregnancy. While animal studies have not shown a risk to the fetus, there are no adequate and well-controlled studies in pregnant women. These medications should be used during pregnancy only if clearly needed and under the guidance of a healthcare professional.

Breastfeeding

The active ingredients in Zantac are excreted in human breast milk. While no specific adverse effects in nursing infants have been documented, the potential for side effects exists. Mothers should consult with their healthcare provider to weigh the benefits of treatment against the potential risks to the nursing infant.

Product Reformulation

The original version of Zantac containing ranitidine was removed from the market due to safety concerns. Current Zantac products contain different active ingredients, such as famotidine. Patients should verify the active ingredient on the product packaging and discuss its safety profile with a doctor or pharmacist if they are pregnant or breastfeeding.

Original Formulation (Ranitidine)

Before its removal from the market, ranitidine (Zantac) was available in the following forms:

• Oral tablets and capsules: These were available in multiple strengths for both prescription and over-the-counter use.
• Oral syrup: A liquid formulation used primarily for patients who had difficulty swallowing pills.
• Injection: A solution for intravenous or intramuscular administration, typically used in hospital settings.

Current Formulation (Zantac 360)

The brand name Zantac was later reintroduced as Zantac 360. This version contains a different active ingredient, famotidine, and is available as:

• Oral tablets: Available in regular and maximum strength versions for over-the-counter use.

Market Withdrawal

In April 2020, the FDA requested the immediate removal of all ranitidine products, including those sold under the brand name Zantac, from the U.S. market. This decision was based on findings that a contaminant called N-Nitrosodimethylamine (NDMA) could increase in the medication over time and when stored at temperatures above room temperature.

NDMA Risks

NDMA is a substance that is classified as a probable human carcinogen. While it is found in low levels in water and foods, the FDA determined that the levels in ranitidine could rise to unacceptable levels during storage, posing a potential risk to public health.

Current Availability

Original Zantac (ranitidine) is no longer FDA-approved for sale. The brand name has since been used for new products, such as Zantac 360, which contain famotidine as the active ingredient. Famotidine is a different acid-reducing medication that has not been associated with the NDMA issues found in ranitidine.

FDA Recall and NDMA Concerns

In April 2020, the U.S. Food and Drug Administration (FDA) requested the immediate removal of all prescription and over-the-counter (OTC) ranitidine products, including those sold under the brand name Zantac. This action followed an investigation into the presence of N-nitrosodimethylamine (NDMA), a substance classified as a probable human carcinogen.

Testing revealed that NDMA levels in ranitidine could increase over time, especially when stored at temperatures higher than room temperature. These levels could potentially exceed the acceptable daily intake limit, posing a health risk to long-term users.

Litigation and Legal Claims

The market withdrawal triggered thousands of lawsuits against the manufacturers of Zantac. These legal actions primarily focus on the following allegations:

• Failure to Warn: Plaintiffs argue that manufacturers were aware, or should have been aware, that ranitidine could degrade into NDMA and failed to inform consumers or healthcare providers of this risk.
• Cancer Links: Many lawsuits involve individuals who developed various types of cancer—including bladder, stomach, esophageal, and liver cancer—after regular use of the medication.
• Scientific Disputes: A significant portion of the legal proceedings has centered on whether scientific evidence definitively proves that the NDMA levels in Zantac are high enough to cause cancer in humans.

Current Status of Zantac Products

It is important to distinguish between the original medication and current products. The Zantac brand name has returned to the market as Zantac 360, which contains famotidine as its active ingredient. Famotidine is a different H2 blocker that has not been associated with the NDMA contamination issues that led to the original recall and subsequent lawsuits.